Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01101399
Other study ID # FER-FID-CHEMO
Secondary ID
Status Completed
Phase Phase 3
First received March 30, 2010
Last updated December 16, 2013
Start date May 2010
Est. completion date November 2013

Study information

Verified date December 2013
Source Vifor Inc.
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics CommissionGermany: Federal Institute for Drugs and Medical DevicesSweden: Medical Products AgencySweden: Regional Ethical Review Board
Study type Interventional

Clinical Trial Summary

Anaemia and functional iron deficiency are common conditions in patients with lymphoid malignancies, conditions which reduce significantly the quality of life and increase morbidity and mortality. Traditionally, Erythropoiesis Stimulating Agents (ESAs) have been used, but recently their use has been shown to have a negative impact on overall survival in different oncology populations. Recently published data suggest that intravenous (IV) iron can be effective in anaemia treatment, even without ESAs. This exploratory study is the first clinical project with ferric carboxymaltose (FCM) in patients with lymphoid malignancies: the data generated may be used for further evaluations of the drug in larger populations. In this study, 1,000 mg of IV iron as FCM will be administered on the same day or within 24 hours before or after chemotherapy treatment. The primary objective is to evaluate the efficacy of FCM in the correction of haemoglobin levels in anaemic subjects with lymphoid malignancies, undergoing chemotherapy. Secondary objectives aim to describe the safety and tolerability of FCM, and the effect of FCM treatment on iron status variables in subjects suffering from lymphoid malignancies.


Description:

Multicentre, randomised, controlled, 2-arm open-label prospective pilot study to evaluate efficacy and safety of FCM in the treatment of anaemia in LPD subjects with functional iron deficiency (FID), undergoing chemotherapy. The subjects will be screened for eligibility within 4 weeks prior to inclusion to receive intravenous (IV) infusions of FCM or no FCM infusions (the subjects may be treated according to the local institutional practice if requiring symptomatic management of anaemia). After randomisation, the visits are scheduled weekly until Week 8.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date November 2013
Est. primary completion date November 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects (male or female) aged =18, suffering from indolent non-Hodgkin's lymphoma, multiple myeloma or chronic lymphocytic leukaemia on any chemotherapy excluding anthracycline containing.

- Life expectancy at least 6 months.

- Received at least 12 weeks (or 3 cycles) of treatment in the current course of chemotherapy before start of iron therapy.

- 8.5 g/dL Hb 10.5 g/dL at time of randomisation.

- Iron-restricted erythropoiesis as defined:

- Stainable iron in bone marrow combined with transferrin saturation (TSAT) =20% OR

- where the evaluation of stainable iron in bone marrow is not possible or available:

- ferritin >30 ng/mL (women) or >40 ng/mL (men) and

- TSAT =20%

- Signed informed consent (before any study procedure).

- Females of child-bearing potential must have a negative urine pregnancy test.

Exclusion Criteria:

- Any anaemia treatment within 4 weeks before inclusion (including red blood cell transfusion, ESA treatment and any oral/parenteral iron supplementation).

- Subjects weighing <35 kg.

- Subjects with increase in Hb during the chemotherapy (>1 g/dL rise between initiation of CT and screening laboratory value).

- Folate deficiency (serum folate <4.5 nmol/L) and/or vitamin B12 deficiency (serum cobalamin <145 pmol/L).

- Ongoing haemolysis defined as serum haptoglobin <0.2 g/L.

- Recent significant bleeding/surgery.

- Monotherapy with immunotherapy agents.

- Known chronic renal failure, creatinine >125 µmol/L.

- Anthracycline containing chemotherapy regimens.

- Clinically relevant active inflammatory disease other than the malignant disease (according to the judgement of the Investigator).

- Clinically relevant ongoing infectious disease including known human immunodeficiency virus.

- Serum-ferritin >800 ng/mL.

- Ongoing significant neurological or psychiatric disorders including psychotic disorders or dementia.

- Significant cardiovascular disease prior to study inclusion including myocardial infarction within 12 months prior to study inclusion, congestive heart failure New York Heart Association (NYHA) Grade III or IV, or poorly controlled hypertension according to the judgment of the Investigator.

- Elevation of liver enzymes (aspartate aminotransferase, alanine aminotransferase) over 3 times above the normal range or known acute hepatic disorder.

- Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(ies), or subject is receiving other investigational agent(s).

- Females who are evidently pregnant (e.g., positive HCG test) or are breast feeding.

- Subject is not using adequate contraceptive precautions. Adequate contraceptive precautions are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra-uterine devices, sexual abstinence or vasectomised partner. Non-childbearing potential includes being surgically sterilised at least 6 months prior to the study or post menopausal, defined as amenorrhea for at least 12 months.

- Subject has known sensitivity to any of the products to be administered during dosing.

- Subject will not be available for follow-up assessment.

- Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Ferric carboxymaltose
Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline. Subjects of bw =66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 4 (Week 2). Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw =66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy.

Locations

Country Name City State
Germany Universitätsklinikum Hamburg-Eppendorf Hamburg
Sweden Department of Medicine, St Görans Hospital (Capio St Görans Sjukhus) Stockholm

Sponsors (1)

Lead Sponsor Collaborator
Vifor Inc.

Countries where clinical trial is conducted

Germany,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in haemoglobin from baseline to Week 4 Weeks 4 post baseline No
Secondary The percentage of subjects with blood haemoglobin increase of at least 1 g/dL in the absence of any red cell transfusion or ESA treatment. 12 weeks post baseline No
Secondary Change in haemoglobin from baseline to Week 6 6 weeks after baseline No
Secondary Change in haemoglobin from baseline to Week 8 8 weeks after baseline No
See also
  Status Clinical Trial Phase
Completed NCT04949165 - Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study N/A
Active, not recruiting NCT02541708 - IV Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania Phase 3
Completed NCT01942460 - Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients Phase 4
Completed NCT00810030 - FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR Phase 3
Completed NCT01047098 - Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation N/A
Completed NCT00298051 - Umbilical Cord Clamping and Infant Iron Status N/A
Completed NCT01135576 - Iron Fortified Beverages and Application in Women Predisposed to Anemia N/A
Withdrawn NCT04320966 - Neurovascular Complications and White Matter Damage in Acquired Anemias
Completed NCT05240677 - Endoscopy in CKD With Iron Deficiency Anemia N/A
Terminated NCT01100879 - Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy Phase 4
Recruiting NCT02487719 - Different Iron Supplements for Prevention of Anemia in Pregnancy Phase 4
Recruiting NCT03232554 - Buxue Yimu Pills for Gynecological Iron-Deficiency Anemia Phase 2
Terminated NCT02341300 - Use of Cast Iron Pots to Improve Maternal Anemia N/A
Completed NCT04318405 - Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).
Completed NCT02998697 - Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia Phase 2/Phase 3
Not yet recruiting NCT03411590 - The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers N/A
Completed NCT05365308 - EHR-based Patient Identification and Panel Management of Patients With Iron Deficiency Anemia N/A
Recruiting NCT01071759 - Effects of Dietary Heme/Non-heme Iron and Helicobacter Pylori (Hp) Infection on Maternal Iron-deficiency Anemia and Fetal Growth Outcomes N/A
Terminated NCT00882414 - Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD) Phase 2
Completed NCT02968368 - Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease Phase 3